Compare RGCO & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGCO | ANIK |
|---|---|---|
| Founded | 1912 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.9M | 200.9M |
| IPO Year | 2005 | 1996 |
| Metric | RGCO | ANIK |
|---|---|---|
| Price | $23.72 | $15.87 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $22.70 | $17.00 |
| AVG Volume (30 Days) | 11.8K | ★ 62.9K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.93% | N/A |
| EPS Growth | 11.21 | ★ 80.16 |
| EPS | ★ 1.31 | N/A |
| Revenue | $95,334,212.00 | ★ $112,819,000.00 |
| Revenue This Year | $11.06 | $5.98 |
| Revenue Next Year | $2.89 | $7.42 |
| P/E Ratio | $17.95 | ★ N/A |
| Revenue Growth | ★ 12.63 | N/A |
| 52 Week Low | $19.68 | $7.90 |
| 52 Week High | $26.63 | $16.28 |
| Indicator | RGCO | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 55.88 | 63.50 |
| Support Level | $20.80 | $13.88 |
| Resistance Level | $26.63 | $15.93 |
| Average True Range (ATR) | 0.88 | 0.54 |
| MACD | -0.05 | 0.15 |
| Stochastic Oscillator | 29.92 | 77.57 |
RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.